Cnbc Exclusive: Eisai U.s. Ceo On Alzheimer's Drug Approval

CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval

CNBC Television

Eisai CEO on Alzheimer's treatment drug trial results

CNBC Television

We believe the risk-benefit profile for our Alzheimer's drug is acceptable, says Eisai U.S. CEO

CNBC Television

Biogen CEO on FDA approval for its Alzheimer's drug

CNBC Television

Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatments

CNBC Television

Biogen and Eisai report successful test on Alzheimer's treatment

CNBC Television

Biogen and Eisai to reveal results of Alzheimer's drug trial

CNBC Television

Biogen Alzheimer's drug could get Medicare coverage in 2025 if approved, says Dr. Scott Gottlieb

CNBC Television

Biogen shares drop despite positive Alzheimer's drug results

CNBC Television

Eli Lilly CEO on FDA approval pathway for Alzheimer's drugs

CNBC Television

Evidence to approve Biogen's Alzheimer's drug was not 'sufficient': Penn's Dr. Jason Karlawi

CNBC Television

Third FDA advisor resigns after Biogen's Alzheimer's drug approval

CNBC Television

Many health systems are already ready for 'Leqembi' roll out, says Eisai CEO Ivan Cheung

CNBC Television

What’s The Controversy Behind Biogen’s Alzheimer’s Drug?

CNBC

Analyst: It's unclear whether Biogen's new Alzheimer's drug will get approved

CNBC Television

FDA approves a new Alzheimer's drug from Eli Lilly

CNBC Television

Biogen CEO Michel Vounatsos on seeking FDA approval for new Alzheimer's drug

CNBC Television

Biogen CEO: Alzheimer's drug shows positive results

CNBC Television

Jefferies' Michael Yee on Biogen as FDA could be on the verge of approving Alzheimer's drug

CNBC Television

FDA approves Biogen's Alzheimer's drug

CNBC Television